Iodide

Iodide

SCHEMBL222931

CC[n+]1cccc2cc(OC)ccc21.[I-]

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 5/20 0.69
KDM4E B2RXH2 4/20 0.50
HTT P42858 3/20 0.50
ALDH1A1 P00352 3/20 0.50
MAPT P10636 2/20 0.50
CYP1A2 P05177 1/20 0.47
CYP2A6 P11509 1/20 0.47
LMNA P02545 2/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45
POLB P06746 1/20 0.43
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
PPM1A P35813 1/20 0.40
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
USP2 O75604 2/20 0.40
RGS12 O14924 1/20 0.40
HSP90AA1 P07900 1/20 0.40
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22034130 0.98 ACHE (0.68) ACHEKDM4EHTTALDH1A1MAPT
Hydrochloric Acid SCHEMBL6231073 0.97 ACHE (0.67) ACHEKDM4EHTTALDH1A1MAPT
Iodide SCHEMBL10815828 0.88 ACHE (0.66) ACHEKDM4EHTTALDH1A1MAPT
Iodide SCHEMBL17187192 0.83 KDM4E (0.65) ACHEKDM4EHTTALDH1A1CYP1A2
SCHEMBL10814162 0.80 ACHE (0.62) ACHEKDM4EHTTALDH1A1MAPT
Bromide SCHEMBL29389671 0.80 KDM4E (0.61) ACHEKDM4EHTTALDH1A1CYP1A2
SCHEMBL30914704 0.79 ACHE (0.60) ACHEBCHE
Bromide SCHEMBL10812845 0.79 ACHE (0.60) ACHEKDM4EHTTALDH1A1MAPT
Bromide SCHEMBL2340311 0.79 ACHE (0.97) ACHEKDM4EHTTALDH1A1CYP1A2
SCHEMBL29425198 0.78 ACHE (0.55) ACHEKDM4EHTTALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1951329-A In-vivo photosensitive blood kalium sensor and preparation method thereof UNIV ZHONGSHAN HOSPITAL FUDAN (CN) 2007-04-25 CN claimed
US-6662039-B2 Measuring response to calcium influx with fluorescent indicator THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2003-12-09 US claimed
US-12571798-B2 Cancer biomarkers and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-03-10 US disclosed
US-12332245-B2 Cancer biomarkers and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-06-17 US disclosed
EP-3796002-B1 CANCER BIOMARKERS AND METHODS OF USE THEREOF UNIV CALIFORNIA (US) 2023-11-22 EP disclosed
US-20230204591-A1 CANCER BIOMARKERS AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-06-29 US disclosed
EP-3796002-A1 CANCER BIOMARKERS AND METHODS OF USE THEREOF The Regents of The University of California (US) 2021-03-24 EP disclosed
US-10955345-B2 Relating to remote sensing BAE SYSTEMS PLC (GB) 2021-03-23 US disclosed
US-10852201-B2 Remote sensing BAE SYSTEMS PLC (GB) 2020-12-01 US disclosed
EP-3508854-A1 CANCER BIOMARKERS AND METHODS OF USE THEREOF The Regents of The University of California (US) 2019-07-10 EP disclosed
EP-3173487-B1 DEVICE FOR DETECTION OF HALOGENATED HYDROCARBONS UNIV MASARYKOVA (CZ) 2019-02-20 EP disclosed
US-20040033500-A1 Excitatory glycine receptors and methods THE BURNHAM INSTITUTE 2004-02-19 US disclosed
US-20030092004-A1 Excitatory glycine receptors and methods LIPTON STUART A (US) 2003-05-15 US disclosed
US-6544794-B1 Frozen thin film sample in contact with water soluble gel containing indicator; exposure to light SHISEIDO COMPANY, LTD. (JP) 2003-04-08 US disclosed
WO-2003016479-A2 EXCITATORY GLYCINE RECEPTORS AND METHODS THE BURNHAM INSTITUTE (US) 2003-02-27 WO disclosed
US-20030021810-A1 Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling UAB RESEARCH FOUNDATION, THE 2003-01-30 US disclosed
WO-2003000203-A2 CHLOROTOXIN INHIBITION OF CELL INVASION, CANCER METASTASIS, ANGIOGENESIS AND TISSUE REMODELING UAB RESEARCH FOUNDATION (US) 2003-01-03 WO disclosed
EP-1234878-A1 USE OF DISEASE-ASSOCIATED GENE Takeda Chemical Industries, Ltd. (JP) 2002-08-28 EP disclosed
EP-1154261-A2 Imaging of ion distribution in tissue SHISEIDO COMPANY LIMITED (JP) 2001-11-14 EP disclosed
WO-2001033219-A2 ION CHANNEL PERMEABILITY BIOFOCUS DISCOVERY LIMITED (GB) 2001-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12571798-B2 Cancer biomarkers and methods of use thereof MKI67, BRCA1, CD68 ACHE 4641/4885KDM4E 2190/4885HTT 4490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.